Some of our press releases are protected by a log-in. These news are marked with a little padlock icon. How our medicines can be prescribed by doctors and the regulatory rules under which we operate differ between countries. Additionally, in most countries we are not permitted to advertise medicines to members of the public. Non-promotional information on our products can therefore only be accessed after registering with Daiichi Sankyo or by using your DocCheck login.
-
Daiichi Sankyo2021-11-21 16:27:52Quizartinib Added to Chemotherapy Demonstrates Superior Overall Survival Compared to Chemotherapy Alone in
-
Daiichi Sankyo2021-11-18 11:23:39TROPION-Breast01 Phase 3 Trial of Datopotamab Deruxtecan Initiated in Patients with Hormone Receptor Positive,
-
Daiichi Sankyo2021-11-02 18:39:15Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for the Treatment of HER2 Positive
-
Daiichi Sankyo2021-10-24 15:53:34Second Clinical Trial Collaboration Initiated to Evaluate Datopotamab Deruxtecan in Combination with KEYTRUDA®
-
Daiichi Sankyo2021-10-04 08:46:17ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Patients with HER2 Positive Metastatic Breast
-
Daiichi Sankyo2021-09-20 13:45:17Datopotamab Deruxtecan Shows Encouraging Tumor Response in Patients with Advanced Non-Small Cell Lung Cancer
-
Daiichi Sankyo2021-09-20 13:40:42ENHERTU® Demonstrated Robust and Durable Tumor Response of 54.9% in Patients with HER2 Mutant Metastatic
-
Daiichi Sankyo2021-09-20 13:36:34ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in
-
Daiichi Sankyo2021-09-20 13:34:15ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced
-
Daiichi Sankyo2021-09-20 13:29:26DS-7300 Data at ESMO Shows Promising Early Clinical Activity in Patients with Advanced Solid Cancers